Key result
IL-35 pretreatment preserves cardiac function and blunts myocardial inflammation in LPS-induced heart injury.
Why the study?
Targeting inflammation is promising for treating LPS-induced sepsis and heart injury, but the role of interleukin-35 remained obscure.
Does pretreatment with a plasmid encoding IL-35 prevent lipopolysaccharide-induced heart injury in mice?
Does pretreatment with a plasmid encoding IL-35 prevent lipopolysaccharide-induced heart injury in mice?
IL-35 pretreatment attenuates cardiac inflammation, apoptosis, and fibrosis in LPS-induced sepsis models, suggesting it as a potential therapeutic target for sepsis-related cardiac injury.
Answers are grounded in this paper and cite their sources.
IL-35 may protect against LPS-induced cardiac injury in mice; hypothesis-generating and should not yet inform clinical practice.
Previous studies have demonstrated that targeting inflammation is a promising strategy for treating lipopolysaccharide (LPS)-induced sepsis and related heart injury. Interleukin-35 (IL-35), which consists of two subunits, Epstein–Barr virus-induced gene 3 (EBI3) and p35, is an immunosuppressive cytokine of the IL-12 family and exhibits strong anti-inflammatory activity. However, the role of IL-35 in LPS-induced heart injury remains obscure. In this study, we explored the role of IL-35 in heart injury induced by LPS and its potential mechanisms. Mice were treated with a plasmid encoding IL-35 (pIL-35) and then injected intraperitoneally (ip) with LPS (10 mg/kg). Cardiac function was assessed by echocardiography 12 h later. LPS apparently decreased the expression of EBI3 and p35 and caused cardiac dysfunction and pathological changes, which were significantly improved by pIL-35 pretreatment. Moreover, pIL-35 pretreatment significantly decreased the levels of cardiac proinflammatory cytokines including TNF-α, IL-6, and IL-1β, and the NLRP3 inflammasome. Furthermore, increased BCL-2 levels and decreased BAX levels inhibited apoptosis, and LPS-induced upregulation of the expression of pro-fibrotic genes (MMP2 and MMP9) was inhibited. Further investigation indicated that pIL-35 pretreatment suppressed the activation of the cardiac NF-κBp65 and TGF-β1/Smad2/3 signaling pathways in LPS-treated mice. Similar cardioprotective effects of IL-35 pretreatment were observed in mouse myocardial fibroblasts challenged with LPS in vitro. In summary, IL-35 pretreatment can attenuate cardiac inflammation, apoptosis, and fibrosis induced by LPS, implicating IL-35 as a promising therapeutic target in sepsis-related cardiac injury.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2020) studied Lipopolysaccharide (LPS)-induced heart injury (n=40). Interleukin-35 (IL-35) pretreatment vs. PBS (Control) was evaluated on Cardiac function (EF% and FS%) and pathological changes (p=<0.05). Interleukin-35 pretreatment significantly improved cardiac function and attenuated inflammation, apoptosis, and fibrosis in a mouse model of lipopolysaccharide-induced heart injury.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: